Yuankun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yuankun Liu has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Songyun Zhao
Department of Neurosurgery The Affiliated Wuxi People's Hospital of Nanjing Medical University Wuxi China
4 shared publicationsWei Ji
Department of Neurosurgery The Affiliated Wuxi People's Hospital of Nanjing Medical University Wuxi China
3 shared publicationsChao Cheng
Department of Neurosurgery The Affiliated Wuxi People's Hospital of Nanjing Medical University Wuxi China
2 shared publications- Chao Cheng
Department of Neurosurgery, Wuxi People’s Hospital, China
2 shared publications Hao Zhuang
Department of Neurosurgery, Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214000, China; Wuxi Medical Center of Nanjing Medical University, Wuxi 214000, China
2 shared publicationsJunfei Shao
Department of Neurosurgery, The Affiliated Wuxi People’s Hospital of Nanjing Medical University
2 shared publications
Latest Publications
- Open Access
- 8 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1759811
Integrating multiomics to elucidate the role of chromatin remodeling in glioma and the antitumor mechanisms and therapeutic potential of targeting LMNA
Background: Glioma is a highly aggressive central nervous system malignancy characterized by poor clinical outcomes. While chromatin remodeling is fundamentally linked to tumorigenesis, its precise roles and underlying mechanisms in glioma remain elusive. Consequently, developing robust prognostic tools and identifying viable therapeutic targets are critical priorities. Methods: Leveraging RNA-seq profiles from the CGGA, GTEx, and TCGA cohorts, we identified chromatin remodeling-related genes (CRRGs) differentially expressed between glioma and normal brain tissues. We stratified patients into distinct molecular subtypes using consensus clustering and engineered a prognostic signature by systematically screening 117 machine-learning algorithm combinations. The expression patterns of core signature genes were cross-validated using single-cell RNA sequencing, spatial transcriptomics, and proteomic data. Finally, we interrogated the functional role of LMNA through in vitro and in vivo assays, complementing these studies with virtual screening to identify potential LMNA-targeting compounds. Results: Consensus clustering segregated gliomas into two CRRG-based subtypes, with Subgroup 2 patients experiencing significantly better prognoses. We pinpointed 28 glioma-specific DECRRGs and derived an optimal SuperPC-based model that robustly stratified patients into high- and low-risk cohorts. LMNA, a core model gene markedly upregulated in glioma and correlated with poor survival, was advanced for experimental validation. Functionally, LMNA depletion severely impaired tumor cell proliferation and invasion in vitro , and potently suppressed tumor growth in vivo . Furthermore, molecular docking analyses identified four natural compounds as candidate LMNA inhibitors. Conclusion: The CRRG-based prognostic signature developed herein demonstrates robust clinical utility for risk stratification. Crucially, our findings highlight LMNA as a potential prognostic biomarker and a promising therapeutic target in glioma.
- 8 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1759811
Open AccessIntegrating multiomics to elucidate the role of chromatin remodeling in glioma and the antitumor mechanisms and therapeutic potential of targeting LMNA
Background: Glioma is a highly aggressive central nervous system malignancy characterized by poor clinical outcomes. While chromatin remodeling is fundamentally linked to tumorigenesis, its precise roles and underlying mechanisms in glioma remain elusive. Consequently, developing robust prognostic tools and identifying viable therapeutic targets are critical priorities. Methods: Leveraging RNA-seq profiles from the CGGA, GTEx, and TCGA cohorts, we identified chromatin remodeling-related genes (CRRGs) differentially expressed between glioma and normal brain tissues. We stratified patients into distinct molecular subtypes using consensus clustering and engineered a prognostic signature by systematically screening 117 machine-learning algorithm combinations. The expression patterns of core signature genes were cross-validated using single-cell RNA sequencing, spatial transcriptomics, and proteomic data. Finally, we interrogated the functional role of LMNA through in vitro and in vivo assays, complementing these studies with virtual screening to identify potential LMNA-targeting compounds. Results: Consensus clustering segregated gliomas into two CRRG-based subtypes, with Subgroup 2 patients experiencing significantly better prognoses. We pinpointed 28 glioma-specific DECRRGs and derived an optimal SuperPC-based model that robustly stratified patients into high- and low-risk cohorts. LMNA, a core model gene markedly upregulated in glioma and correlated with poor survival, was advanced for experimental validation. Functionally, LMNA depletion severely impaired tumor cell proliferation and invasion in vitro , and potently suppressed tumor growth in vivo . Furthermore, molecular docking analyses identified four natural compounds as candidate LMNA inhibitors. Conclusion: The CRRG-based prognostic signature developed herein demonstrates robust clinical utility for risk stratification. Crucially, our findings highlight LMNA as a potential prognostic biomarker and a promising therapeutic target in glioma.
- 20 April 2025
- Published by Wiley in Journal of Cellular Physiology
- Vol. 240 (4) , e70037
CBLB Regulates MAPK‐P38 Pathway via MAP3K9 Ubiquitination to Inhibit GBM Cell Invasion and Migration
Glioma cells exhibit high invasiveness and have the ability to evade surgical resection, radiotherapy, and chemotherapy, which are major factors contributing to the challenges in effective treatment and recurrence. The ubiquitin‐proteasome system (UPS) plays a crucial role in posttranslational modification, significantly contributing to the aggressive progression of glioblastoma (GBM). This study identified the E3 ubiquitin ligase CBLB as a crucial and abnormally regulated component of the UPS in GBM, noting its significant downregulation compared to normal brain tissue and its negative correlation with malignant phenotypes and poor prognosis. Experimental studies, both in vitro and in vivo, have shown that CBLB can inhibit the migration and invasion of GBM cells. Mechanistically, CBLB directly interacts with MAP3K9 through its RING domain, leading to K48‐K63‐linked polyubiquitination at the Lys 193 site, thereby promoting MAP3K9 proteasomal‐mediated degradation. MAP3K9 downregulation suppresses MAPK‐P38 pathway activation. This study identifies CBLB as a tumor suppressor that modulates the MAPK‐P38 signaling pathway by promoting the polyubiquitination and degradation of MAP3K9, offering a new therapeutic approach for GBM treatment.
- 20 April 2025
- Published by Wiley in Journal of Cellular Physiology
- Vol. 240 (4) , e70037
CBLB Regulates MAPK‐P38 Pathway via MAP3K9 Ubiquitination to Inhibit GBM Cell Invasion and Migration
Glioma cells exhibit high invasiveness and have the ability to evade surgical resection, radiotherapy, and chemotherapy, which are major factors contributing to the challenges in effective treatment and recurrence. The ubiquitin‐proteasome system (UPS) plays a crucial role in posttranslational modification, significantly contributing to the aggressive progression of glioblastoma (GBM). This study identified the E3 ubiquitin ligase CBLB as a crucial and abnormally regulated component of the UPS in GBM, noting its significant downregulation compared to normal brain tissue and its negative correlation with malignant phenotypes and poor prognosis. Experimental studies, both in vitro and in vivo, have shown that CBLB can inhibit the migration and invasion of GBM cells. Mechanistically, CBLB directly interacts with MAP3K9 through its RING domain, leading to K48‐K63‐linked polyubiquitination at the Lys 193 site, thereby promoting MAP3K9 proteasomal‐mediated degradation. MAP3K9 downregulation suppresses MAPK‐P38 pathway activation. This study identifies CBLB as a tumor suppressor that modulates the MAPK‐P38 signaling pathway by promoting the polyubiquitination and degradation of MAP3K9, offering a new therapeutic approach for GBM treatment.
- Open Access
- 9 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-13
The promise of mitochondria in the treatment of glioblastoma: a brief review
Glioblastoma (GBM) is a prevalent and refractory type of brain tumor. Over the past two decades, there have been minimal advancements in GBM therapy. The current standard treatment involves surgical excision followed by radiation and chemotherapy. Compared to other tumors, GBM is more challenging to treat due to the presence of glioma stem-like cells (GSCs) and the blood–brain barrier, resulting in an extremely low survival rate. Mitochondria play a critical role in tumor respiration, metabolism, and multiple signaling pathways involved in tumor formation, progression, and cell apoptosis. Consequently, mitochondria represent promising targets for developing novel anticancer agents, including those targeting oxidative phosphorylation, reactive oxygen species (ROS), mitochondrial transfer, and mitophagy. This review outlines the mitochondrial-related therapeutic targets in GBM, highlighting the potential of mitochondria as a target for GBM treatment.
- 9 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-13
Open AccessThe promise of mitochondria in the treatment of glioblastoma: a brief review
Glioblastoma (GBM) is a prevalent and refractory type of brain tumor. Over the past two decades, there have been minimal advancements in GBM therapy. The current standard treatment involves surgical excision followed by radiation and chemotherapy. Compared to other tumors, GBM is more challenging to treat due to the presence of glioma stem-like cells (GSCs) and the blood–brain barrier, resulting in an extremely low survival rate. Mitochondria play a critical role in tumor respiration, metabolism, and multiple signaling pathways involved in tumor formation, progression, and cell apoptosis. Consequently, mitochondria represent promising targets for developing novel anticancer agents, including those targeting oxidative phosphorylation, reactive oxygen species (ROS), mitochondrial transfer, and mitophagy. This review outlines the mitochondrial-related therapeutic targets in GBM, highlighting the potential of mitochondria as a target for GBM treatment.
- Open Access
- 18 January 2025
- Published by Elsevier in Experimental Neurology
- Vol. 386, 115152
Overexpressed CD73 attenuates GSDMD-mediated astrocyte pyroptosis induced by cerebral ischemia-reperfusion injury through the A2B/NF-κB pathway
- 18 January 2025
- Published by Elsevier in Experimental Neurology
- Vol. 386, 115152
Open AccessOverexpressed CD73 attenuates GSDMD-mediated astrocyte pyroptosis induced by cerebral ischemia-reperfusion injury through the A2B/NF-κB pathway
- Open Access
- 15 September 2024
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 26 (1) , 1-17
Identification of Disulfidptosis-Related Genes in Ischemic Stroke by Combining Single-Cell Sequencing, Machine Learning Algorithms, and In Vitro Experiments
Background Ischemic stroke (IS) is a severe neurological disorder with a pathogenesis that remains incompletely understood. Recently, a novel form of cell death known as disulfidptosis has garnered significant attention in the field of ischemic stroke research. This study aims to investigate the mechanistic roles of disulfidptosis-related genes (DRGs) in the context of IS and to examine their correlation with immunopathological features. Methods To enhance our understanding of the mechanistic underpinnings of disulfidptosis in IS, we initially retrieved the expression profile of peripheral blood from human IS patients from the GEO database. We then utilized a suite of machine learning algorithms, including LASSO, random forest, and SVM-RFE, to identify and validate pivotal genes. Furthermore, we developed a predictive nomogram model, integrating multifactorial logistic regression analysis and calibration curves, to evaluate the risk of IS. For the analysis of single-cell sequencing data, we employed a range of analytical tools, such as "Monocle" and "CellChat," to assess the status of immune cell infiltration and to characterize intercellular communication networks. Additionally, we utilized an oxygen–glucose deprivation (OGD) model to investigate the effects of SLC7A11 overexpression on microglial polarization. Results This study successfully identified key genes associated with disulfidptosis and developed a reliable nomogram model using machine learning algorithms to predict the risk of ischemic stroke. Examination of single-cell sequencing data showed a robust correlation between disulfidptosis levels and the infiltration of immune cells. Furthermore, "CellChat" analysis elucidated the intricate characteristics of intercellular communication networks. Notably, the TNF signaling pathway was found to be intimately linked with the disulfidptosis signature in ischemic stroke. In an intriguing finding, the OGD model demonstrated that SLC7A11 expression suppresses M1 polarization while promoting M2 polarization in microglia. Conclusion The significance of our findings lies in their potential to shed light on the pathogenesis of ischemic stroke, particularly by underscoring the pivotal role of disulfidptosis-related genes (DRGs). These insights could pave the way for novel therapeutic strategies targeting DRGs to mitigate the impact of ischemic stroke.
- 15 September 2024
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 26 (1) , 1-17
Open AccessIdentification of Disulfidptosis-Related Genes in Ischemic Stroke by Combining Single-Cell Sequencing, Machine Learning Algorithms, and In Vitro Experiments
Background Ischemic stroke (IS) is a severe neurological disorder with a pathogenesis that remains incompletely understood. Recently, a novel form of cell death known as disulfidptosis has garnered significant attention in the field of ischemic stroke research. This study aims to investigate the mechanistic roles of disulfidptosis-related genes (DRGs) in the context of IS and to examine their correlation with immunopathological features. Methods To enhance our understanding of the mechanistic underpinnings of disulfidptosis in IS, we initially retrieved the expression profile of peripheral blood from human IS patients from the GEO database. We then utilized a suite of machine learning algorithms, including LASSO, random forest, and SVM-RFE, to identify and validate pivotal genes. Furthermore, we developed a predictive nomogram model, integrating multifactorial logistic regression analysis and calibration curves, to evaluate the risk of IS. For the analysis of single-cell sequencing data, we employed a range of analytical tools, such as "Monocle" and "CellChat," to assess the status of immune cell infiltration and to characterize intercellular communication networks. Additionally, we utilized an oxygen–glucose deprivation (OGD) model to investigate the effects of SLC7A11 overexpression on microglial polarization. Results This study successfully identified key genes associated with disulfidptosis and developed a reliable nomogram model using machine learning algorithms to predict the risk of ischemic stroke. Examination of single-cell sequencing data showed a robust correlation between disulfidptosis levels and the infiltration of immune cells. Furthermore, "CellChat" analysis elucidated the intricate characteristics of intercellular communication networks. Notably, the TNF signaling pathway was found to be intimately linked with the disulfidptosis signature in ischemic stroke. In an intriguing finding, the OGD model demonstrated that SLC7A11 expression suppresses M1 polarization while promoting M2 polarization in microglia. Conclusion The significance of our findings lies in their potential to shed light on the pathogenesis of ischemic stroke, particularly by underscoring the pivotal role of disulfidptosis-related genes (DRGs). These insights could pave the way for novel therapeutic strategies targeting DRGs to mitigate the impact of ischemic stroke.
- Open Access
- 15 August 2024
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 170 (1) , 101-117
Exploring the prognostic value of BRMS1 + microglia based on single-cell anoikis regulator patterns in the immunologic microenvironment of GBM
Background: Anoikis is a specialized form of programmed cell death induced by the loss of cell adhesion to the extracellular matrix (ECM). Acquisition of anoikis resistance is a significant marker for cancer cell invasion, metastasis, therapy resistance, and recurrence. Although current research has identified multiple factors that regulate anoikis resistance, the pathological mechanisms of anoikis-mediated tumor microenvironment (TME) in glioblastoma (GBM) remain largely unexplored. Methods: Utilizing single-cell RNA sequencing (scRNA-seq) data and employing non-negative matrix factorization (NMF), we identified and characterized TME cell clusters with distinct anoikis-associated gene signatures. Prognostic and therapeutic response analyses were conducted using TCGA and CGGA datasets to assess the clinical significance of different TME cell clusters. The spatial relationship between BRMS1 + microglia and tumor cells was inferred from spatial transcriptome RNA sequencing (stRNA-seq) data. To simulate the tumor immune microenvironment, co-culture experiments were performed with microglia (HMC3) and GBM cells (U118/U251), and microglia were transfected with a BRMS1 overexpression lentivirus. Western blot or ELISA were used to detect BRMS1, M2 macrophage-specific markers, PI3K/AKT signaling proteins, and apoptosis-related proteins. The proliferation and apoptosis capabilities of tumor cells were evaluated using CCK-8, colony formation, and apoptosis assays, while the invasive and migratory abilities of tumor cells were assessed using Transwell assays. Results: NMF-based analysis successfully identified CD8 + T cell and microglia cell clusters with distinct gene signature characteristics. Trajectory analysis, cell communication, and gene regulatory network analyses collectively indicated that anoikis-mediated TME cell clusters can influence tumor cell development through various mechanisms. Notably, BRMS1 + AP-Mic exhibited an M2 macrophage phenotype and had significant cell communication with malignant cells. Moreover, high expression of BRMS1 + AP-Mic in TCGA and CGGA datasets was associated with poorer survival outcomes, indicating its detrimental impact on immunotherapy. Upregulation of BRMS1 in microglia may lead to M2 macrophage polarization, activate the PI3K/AKT signaling pathway through SPP1/CD44-mediated cell interactions, inhibit tumor cell apoptosis, and promote tumor proliferation and invasion. Conclusion: This pioneering study used NMF-based analysis to reveal the important predictive value of anoikis-regulated TME in GBM for prognosis and immunotherapeutic response. BRMS1 + microglial cells provide a new perspective for a deeper understanding of the immunosuppressive microenvironment of GBM and could serve as a potential therapeutic target in the future.
- 15 August 2024
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 170 (1) , 101-117
Open AccessExploring the prognostic value of BRMS1 + microglia based on single-cell anoikis regulator patterns in the immunologic microenvironment of GBM
Background: Anoikis is a specialized form of programmed cell death induced by the loss of cell adhesion to the extracellular matrix (ECM). Acquisition of anoikis resistance is a significant marker for cancer cell invasion, metastasis, therapy resistance, and recurrence. Although current research has identified multiple factors that regulate anoikis resistance, the pathological mechanisms of anoikis-mediated tumor microenvironment (TME) in glioblastoma (GBM) remain largely unexplored. Methods: Utilizing single-cell RNA sequencing (scRNA-seq) data and employing non-negative matrix factorization (NMF), we identified and characterized TME cell clusters with distinct anoikis-associated gene signatures. Prognostic and therapeutic response analyses were conducted using TCGA and CGGA datasets to assess the clinical significance of different TME cell clusters. The spatial relationship between BRMS1 + microglia and tumor cells was inferred from spatial transcriptome RNA sequencing (stRNA-seq) data. To simulate the tumor immune microenvironment, co-culture experiments were performed with microglia (HMC3) and GBM cells (U118/U251), and microglia were transfected with a BRMS1 overexpression lentivirus. Western blot or ELISA were used to detect BRMS1, M2 macrophage-specific markers, PI3K/AKT signaling proteins, and apoptosis-related proteins. The proliferation and apoptosis capabilities of tumor cells were evaluated using CCK-8, colony formation, and apoptosis assays, while the invasive and migratory abilities of tumor cells were assessed using Transwell assays. Results: NMF-based analysis successfully identified CD8 + T cell and microglia cell clusters with distinct gene signature characteristics. Trajectory analysis, cell communication, and gene regulatory network analyses collectively indicated that anoikis-mediated TME cell clusters can influence tumor cell development through various mechanisms. Notably, BRMS1 + AP-Mic exhibited an M2 macrophage phenotype and had significant cell communication with malignant cells. Moreover, high expression of BRMS1 + AP-Mic in TCGA and CGGA datasets was associated with poorer survival outcomes, indicating its detrimental impact on immunotherapy. Upregulation of BRMS1 in microglia may lead to M2 macrophage polarization, activate the PI3K/AKT signaling pathway through SPP1/CD44-mediated cell interactions, inhibit tumor cell apoptosis, and promote tumor proliferation and invasion. Conclusion: This pioneering study used NMF-based analysis to reveal the important predictive value of anoikis-regulated TME in GBM for prognosis and immunotherapeutic response. BRMS1 + microglial cells provide a new perspective for a deeper understanding of the immunosuppressive microenvironment of GBM and could serve as a potential therapeutic target in the future.
- Open Access
- 1 January 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024 (1) , 5521016
The Expression Profiles and Clinical Significance of Mixed Lineage Kinases in Glioma
Mixed lineage kinases (MLKs), comprising seven members: MLK1‐4, dual leucine zipper kinase (DLK), leucine zipper kinase (LZK), and sterile alpha motif and leucine zipper containing kinase (ZAK), belong to the mitogen‐activated protein kinase kinase kinase (MAP3K) family. These kinases are implicated in the progression of numerous cancers by activating mitogen‐activated protein kinase (MAPK) cascades or functioning as ser/thr and tyr kinases. However, their specific roles in glioma remain elusive. In the present study, we utilized bioinformatics approaches to investigate the expression patterns of MLKs in low‐grade gliomas (LGG) and glioblastoma multiforme (GBM). Additionally, we analyzed their clinical significance and delved into the potential mechanisms underlying MLK activity as well as their association with tumor‐immune infiltrating cells (TIICs) in glioma. Furthermore, we conducted in vitro studies to elucidate the functional roles of MLK1‐2 in glioma. Our findings revealed that the expressions of MLK1‐2 were conspicuously downregulated in GBM and positively correlated with patients’ overall survival. Conversely, ZAK exhibited an opposing trend. Notably, our newly devised risk score model exhibited superior performance in predicting patient prognoses. Moreover, we analyzed the potential mechanisms of MLK activity and its interplay with tumor immune infiltration. Last, we validated the antitumor effect of MLK1‐2 at the in vitro level. In summary, our study sheds new insights into the roles of MLKs in glioma, particularly MLK1‐2, and their potential as therapeutic targets.
- 1 January 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024 (1) , 5521016
Open AccessThe Expression Profiles and Clinical Significance of Mixed Lineage Kinases in Glioma
Mixed lineage kinases (MLKs), comprising seven members: MLK1‐4, dual leucine zipper kinase (DLK), leucine zipper kinase (LZK), and sterile alpha motif and leucine zipper containing kinase (ZAK), belong to the mitogen‐activated protein kinase kinase kinase (MAP3K) family. These kinases are implicated in the progression of numerous cancers by activating mitogen‐activated protein kinase (MAPK) cascades or functioning as ser/thr and tyr kinases. However, their specific roles in glioma remain elusive. In the present study, we utilized bioinformatics approaches to investigate the expression patterns of MLKs in low‐grade gliomas (LGG) and glioblastoma multiforme (GBM). Additionally, we analyzed their clinical significance and delved into the potential mechanisms underlying MLK activity as well as their association with tumor‐immune infiltrating cells (TIICs) in glioma. Furthermore, we conducted in vitro studies to elucidate the functional roles of MLK1‐2 in glioma. Our findings revealed that the expressions of MLK1‐2 were conspicuously downregulated in GBM and positively correlated with patients’ overall survival. Conversely, ZAK exhibited an opposing trend. Notably, our newly devised risk score model exhibited superior performance in predicting patient prognoses. Moreover, we analyzed the potential mechanisms of MLK activity and its interplay with tumor immune infiltration. Last, we validated the antitumor effect of MLK1‐2 at the in vitro level. In summary, our study sheds new insights into the roles of MLKs in glioma, particularly MLK1‐2, and their potential as therapeutic targets.
- 1 May 2021
- Published by AIP Publishing in Review of Scientific Instruments
- Vol. 92 (5) , 053501
Toroidal soft x-ray array on the EXL-50 spherical tokamak
A toroidal soft x-ray array system for spectrum and intensity measurements on the EXL-50 spherical tokamak is described. Silicon drift detectors and digital multichannel analyzers are adopted for all 21 channels of the array, and an average energy resolution of 147 eV at 5.89 keV has been achieved at count rates over 500 kcps. In total, 20 channels of the array are symmetrically observed in both co- and counter-current directions on the EXL-50 mid-plane with a spatial resolution of around 10 cm, and the remaining one serves as a background reference channel. Tungsten emissions from tungsten coating of the limiters on the central post are observed. The influence of hard x rays on measured soft x-ray spectra and system operation is discussed.
- 1 May 2021
- Published by AIP Publishing in Review of Scientific Instruments
- Vol. 92 (5) , 053501
Toroidal soft x-ray array on the EXL-50 spherical tokamak
A toroidal soft x-ray array system for spectrum and intensity measurements on the EXL-50 spherical tokamak is described. Silicon drift detectors and digital multichannel analyzers are adopted for all 21 channels of the array, and an average energy resolution of 147 eV at 5.89 keV has been achieved at count rates over 500 kcps. In total, 20 channels of the array are symmetrically observed in both co- and counter-current directions on the EXL-50 mid-plane with a spatial resolution of around 10 cm, and the remaining one serves as a background reference channel. Tungsten emissions from tungsten coating of the limiters on the central post are observed. The influence of hard x rays on measured soft x-ray spectra and system operation is discussed.
- 1 December 2020
- Published by Elsevier in Fusion Engineering and Design
- Vol. 161, 111904
Preliminary design of the AXUV diode measurements for the HL-2M tokamak
- 1 December 2020
- Published by Elsevier in Fusion Engineering and Design
- Vol. 161, 111904
Preliminary design of the AXUV diode measurements for the HL-2M tokamak
- 1 August 2011
- Published by Elsevier in Journal of Nuclear Materials
- Vol. 415 (1) , S475-S478
Blob birth and propagation characteristics on the HL-2A tokamak
- 1 August 2011
- Published by Elsevier in Journal of Nuclear Materials
- Vol. 415 (1) , S475-S478
Blob birth and propagation characteristics on the HL-2A tokamak